On September 8, 2022 Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, reported that its Chief Financial Officer, Ryan Confer, will be providing a virtual overview of the Company’s gene therapies for cancer and diabetes at the following investor conference in September 2022 (Press release, Genprex, SEP 8, 2022, View Source [SID1234619248]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Event: H.C. Wainwright 24th Annual Global Investment Conference

Conference Dates: September 12-14, 2022

Virtual Presentation: On-demand within the virtual platform for all delegates starting September 12 at 7:00 a.m. ET

Presenter: Ryan Confer, Genprex’s Chief Financial Officer

Mr. Confer will deliver an overview of the Company’s pioneering gene therapies for cancer and diabetes and Company management will be available for in-person one-on-one meetings with investors through the H.C. Wainwright conference platform.

A recording of this presentation will be available for replay on Genprex’s website for a period of time.